Pfizer reports a jump in Q4 net income to $9.45b, or $1.32/share, versus $2.73b, or $0.37/share, helped by the $7.9 billion profit from the sale of its consumer division to Johnson & Johnson. Adjusted earnings of $0.43/share beat analysts' average estimate of $0.42/share, but is a 12% decline from $0.49/share last Q4. Revenue totaled $12.6b, a 0.4% increase y-o-y, also beating analysts' estimate of $12.26b. Sales of prescription drugs, which account for more than 90% of Pfizer's revenues increased by approx. $20m to $11.67b, hurt most noticeably by a 79% drop in worldwide sales of Zoloft to $166m. In its analyst meeting this afternoon in New York, Pfizer will discuss its guidance for 2007 and CEO Jeffrey Kindler is expected to elaborate on additional cost-cutting plans. In pre-market trading Pfizer's shares were up about 0.8% at $27.45, from Friday's close of $27.22 on volume slightly over 100k.
• Sources: Earnings press release, Bloomberg, WSJ
• Related commentary: Pfizer CEO Kindler Set To Overhaul Budget, Antidepressant Drug Market: New FDA Warning To Have Limited Impact, Pfizer Trading Well Below Its Intrinsic Value, Howling At The Moon: Dogs and Flying Five 2007 Stock Picks
• Potentially impacted stocks and ETFs: Pfizer (NYSE:PFE). ETFs: iShares Dow Jones US Pharmaceuticals (NYSEARCA:IHE), iShares Dow Jones US Healthcare (NYSEARCA:IYH), Pharmaceutical HOLDRs (NYSEARCA:PPH), Vanguard Health Care (NYSEARCA:VHT), Health Care Select SPDR (NYSEARCA:XLV), First Trust Morningstar Dividend Leaders (NYSEARCA:FDL)
Seeking Alpha's news summaries are combined into a pre-market briefing called Wall Street Breakfast. Get Wall Street Breakfast by email -- it's free and takes only a few seconds to sign up.